Hansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review

Bulletin Express

Sep 11

Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority Review and Approval Procedure on 21 August 2026.

The fast-track designation is based on positive pivotal Phase III ARTEMIS-008 data for patients with small-cell lung cancer (SCLC) whose disease progressed after prior platinum-based chemotherapy.

The company disclosed the development in a voluntary announcement dated 11 September 2026. No additional financial terms or timelines were provided.

Chairlady Zhong Huijuan signed the announcement on behalf of the board, which currently comprises three executive directors and four independent non-executive directors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1182293455"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182293455\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182293455?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-11 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182293455","market":"us","top_or_hot":-1,"title":"Hansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority Review and Approval Procedure on 21 August 2026.</p>\n<p>The fast-track designation is based on positive pivotal Phase III ARTEMIS-008 data for patients with small-cell lung cancer (SCLC) whose disease progressed after prior platinum-based chemotherapy.</p>\n<p>The company disclosed the development in a voluntary announcement dated 11 September 2026. No additional financial terms or timelines were provided.</p>\n<p>Chairlady Zhong Huijuan signed the announcement on behalf of the board, which currently comprises three executive directors and four independent non-executive directors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-11 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority Review and Approval Procedure on 21 August 2026.</p>\n<p>The fast-track designation is based on positive pivotal Phase III ARTEMIS-008 data for patients with small-cell lung cancer (SCLC) whose disease progressed after prior platinum-based chemotherapy.</p>\n<p>The company disclosed the development in a voluntary announcement dated 11 September 2026. No additional financial terms or timelines were provided.</p>\n<p>Chairlady Zhong Huijuan signed the announcement on behalf of the board, which currently comprises three executive directors and four independent non-executive directors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1182293455","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182293455","pubTimestamp":1789116394,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"豪森制药治疗小细胞肺癌的Risvutatug Rezetecan进入NMPA优先审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority Review and Approval Procedure on 21 August 2026.\nThe fast-track designation is based on positive pivotal Phase III ARTEMIS-008 data for patients with small-cell lung cancer (SCLC) whose disease progressed after prior platinum-based chemotherapy.\nThe company disclosed the development in a voluntary announcement dated 11 September 2026. No additional financial terms or timelines were provided.\nChairlady Zhong Huijuan signed the announcement on behalf of the board, which currently comprises three executive directors and four independent non-executive directors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}